Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Novel CD58 Mutation-Related Signature Predicts Prognosis Risk in Diffuse Large B-Cell Lymphoma Patients.

Cancer research and treatment - 1 Jul 2026

Wang Hui-Li, Shang Chun-Yu, Hua Wei, Yin Hua, Li Yue, Liang Jun-Heng, Gao Rui, Pan Bi-Hui, Zhang Xin-Yu, Wu Jia-Zhu, Shen Hao-Rui, Wang Li, Li Jian-Yong, Liang Jin-Hua, Xu Wei

Abstract excerpt

PURPOSE: CD58, a ligand of the CD2 receptor on T cells and natural killer cells, is abnormally expressed in diffuse large B-cell lymphoma (DLBCL). However, data on the value of CD58 mutation (CD58mut) in DLBCL are limited. Here, we aimed to evaluate the characteristics and prognostic value of CD58mut in DLBCL patients. MATERIALS AND METHODS: The available clinical information and corresponding mutation data of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to OXTR gene

Share to Lymphoma, Large B-Cell, Diffuse

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 40744814
DOI: 10.4143/crt.2024.1143
PMCID: PMC13382556

Genes

CD58
CD2
MRO
OXTR
PROM2
RASL11A
RLN1
SIGLEC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Novel CD58 Mutation-Related Signature Predicts Prognosis Risk in Diffuse Large B-Cell Lymphoma Patients.PMID 40744814Read ↗

CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Comprehensive Analysis of TP53 Mutation Characteristics and Identification of Patients with Inferior Prognosis and Enhanced Immune Escape in Diffuse Large B Cell LymphomaSemantic proximity Read ↗

Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.Semantic proximity Read ↗

Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma.Semantic proximity Read ↗

Prognostic Analysis of Diffuse Large B-Cell Lymphoma Patients Based on Clinical Characteristics, TP53 Mutation Status, and Number of Co-mutated GenesSemantic proximity Read ↗

Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review.Semantic proximity Read ↗

CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse.Semantic proximity Read ↗

Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosisSemantic proximity Read ↗

Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.Semantic proximity Read ↗

Identification of M2 macrophage-related genes associated with diffuse large B-cell lymphoma via bioinformatics and machine learning approachesSemantic proximity Read ↗

Immunophenotypic Landscape and Prognosis-Related mRNA Signature in Diffuse Large B Cell LymphomaSemantic proximity Read ↗

Predictive biomarkers and molecular subtypes in DLBCL: insights from PCD gene expression and machine learningSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.